Why Conmed (CNMD) is a Top Momentum Stock for the Long-Term

Group 1 - Zacks Premium offers tools for investors to enhance their stock market confidence and knowledge, including daily updates, research reports, and stock screens [1][2] - The Zacks Style Scores provide ratings based on value, growth, and momentum characteristics, helping investors identify stocks with high potential to outperform the market [2][3] Group 2 - The Value Score identifies attractive and discounted stocks using various financial ratios, appealing to value investors [3] - The Growth Score focuses on a company's future prospects and financial health, analyzing earnings, sales, and cash flow [4] - The Momentum Score helps investors capitalize on price trends by analyzing recent price changes and earnings estimate shifts [5] Group 3 - The VGM Score combines the three Style Scores to identify stocks with the best value, growth, and momentum characteristics, serving as a strong indicator alongside the Zacks Rank [6] - The Zacks Rank model, based on earnings estimate revisions, has shown a historical average annual return of +23.75% for 1 (Strong Buy) stocks since 1988, significantly outperforming the S&P 500 [7][9] Group 4 - CONMED Corporation, a medical products manufacturer, is currently rated 3 (Hold) on the Zacks Rank with a VGM Score of A, indicating potential for investors [11] - The company has a Momentum Style Score of A, with shares increasing by 4.8% over the past four weeks, and an upward revision in earnings estimates for fiscal 2025 [12]